Gore S - Search Results

1

A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.

Lin J, Gilbert J, Rudek MA, Zwiebel JA, Gore S, Jiemjit A, Zhao M, Baker SD, Ambinder RF, Herman JG, Donehower RC, Carducci MA. Lin J, et al. Among authors: gore s. Clin Cancer Res. 2009 Oct 1;15(19):6241-9. doi: 10.1158/1078-0432.CCR-09-0567. Epub 2009 Sep 29. Clin Cancer Res. 2009. PMID: 19789320 Free PMC article. Clinical Trial.

2

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng YC, Grochow LB, Kaufmann SH. Rowinsky EK, et al. Among authors: gore sd. J Clin Oncol. 1994 Oct;12(10):2193-203. doi: 10.1200/JCO.1994.12.10.2193. J Clin Oncol. 1994. PMID: 7931489 Clinical Trial.

3

Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells.

Gore SD, Samid D, Weng LJ. Gore SD, et al. Clin Cancer Res. 1997 Oct;3(10):1755-62. Clin Cancer Res. 1997. PMID: 9815560

4

Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.

Gore SD, Weng LJ, Jones RJ, Cowan K, Zilcha M, Piantadosi S, Burke PJ. Gore SD, et al. Clin Cancer Res. 1995 Mar;1(3):295-303. Clin Cancer Res. 1995. PMID: 9815985 Clinical Trial.

5

A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.

Rowinsky EK, Kaufmann SH, Baker SD, Miller CB, Sartorius SE, Bowling MK, Chen TL, Donehower RC, Gore SD. Rowinsky EK, et al. Among authors: gore sd. Clin Cancer Res. 1996 Dec;2(12):1921-30. Clin Cancer Res. 1996. PMID: 9816150 Clinical Trial.

6

A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia.

Gore SD, Rowinsky EK, Miller CB, Griffin C, Chen TL, Borowitz M, Donehower RC, Burks KL, Armstrong DK, Burke PJ, Grever MR, Kaufmann SH. Gore SD, et al. Clin Cancer Res. 1998 Nov;4(11):2677-89. Clin Cancer Res. 1998. PMID: 9829730 Clinical Trial.

7

Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid.

Yu KH, Weng LJ, Fu S, Piantadosi S, Gore SD. Yu KH, et al. Among authors: gore sd. Leukemia. 1999 Aug;13(8):1258-65. doi: 10.1038/sj.leu.2401468. Leukemia. 1999. PMID: 10450755

8

Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors.

Gore SD, Carducci MA. Gore SD, et al. Expert Opin Investig Drugs. 2000 Dec;9(12):2923-34. doi: 10.1517/13543784.9.12.2923. Expert Opin Investig Drugs. 2000. PMID: 11093362 Review.

9

Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Rowinsky EK, Zabalena Y, Hawkins AL, Burks K, Miller CB. Gore SD, et al. Clin Cancer Res. 2001 Aug;7(8):2330-9. Clin Cancer Res. 2001. PMID: 11489809 Clinical Trial.

10

Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y, Miller CB. Gore SD, et al. Clin Cancer Res. 2002 Apr;8(4):963-70. Clin Cancer Res. 2002. PMID: 11948101 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

834 results

Search Page

Filters